Literature DB >> 18521652

Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports.

Primal P Kaur1, Virginia C Chan, Steven N Berney.   

Abstract

Tumor necrosis factor (TNF)-alpha antagonists successfully modulate the pathogenesis of rheumatoid arthritis (RA). However, little is known about the effect of TNF-alpha blockade on the histology of chronic viral hepatitis. We describe the cases of two patients with RA, one with concurrent chronic hepatitis B virus and the other with hepatitis C virus infection who, as part of their evaluation, underwent liver biopsies while undergoing treatment with a TNF-alpha antagonist.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18521652     DOI： 10.1007/s10067-008-0896-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  10 in total

1.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

Authors:  P Ostuni; C Botsios; L Punzi; P Sfriso; S Todesco
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

2.  Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Authors:  B Kallinowski; K Haseroth; G Marinos; C Hanck; W Stremmel; L Theilmann; M V Singer; S Rossol
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection.

Authors:  J W Fang; W W Shen; A Meager; J Y Lau
Journal:  Am J Gastroenterol       Date:  1996-04       Impact factor: 10.864

4.  Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

Authors:  D R Nelson; H L Lim; C G Marousis; J W Fang; G L Davis; L Shen; M S Urdea; J A Kolberg; J Y Lau
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

5.  Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

Authors:  C H Roux; O Brocq; V Breuil; C Albert; L Euller-Ziegler
Journal:  Rheumatology (Oxford)       Date:  2006-04-07       Impact factor: 7.580

6.  Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment.

Authors:  S Magrin; A Craxi; C Fabiano; R G Simonetti; G Fiorentino; L Marino; O Diquattro; V Di Marco; O Loiacono; R Volpes
Journal:  Hepatology       Date:  1994-02       Impact factor: 17.425

7.  Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Authors:  Marc Michel; Cristophe Duvoux; Cristophe Hezode; Daniel Cherqui
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

Review 8.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

Authors:  Owonayo Oniankitan; Christophe Duvoux; Dominique Challine; Arianne Mallat; Xavier Chevalier; Jean-Michel Pawlotsky; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

10.  Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.

Authors:  Grigorios T Sakellariou; Ioannis Chatzigiannis
Journal:  Clin Rheumatol       Date:  2006-07-25       Impact factor: 3.650
  10 in total
  9 in total

Review 1.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 2.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

Review 3.  Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.

Authors:  María Luisa Manzano-Alonso; Gregorio Castellano-Tortajada
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

Review 4.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156

Review 5.  Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature.

Authors:  Takeshi Kuroda; Yoko Wada; Daisuke Kobayashi; Hiroe Sato; Syuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

Review 6.  Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review.

Authors:  Maurizio Pompili; Marco Biolato; Luca Miele; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Authors:  Filip De Keyser
Journal:  Curr Rheumatol Rev       Date:  2011-02

8.  Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Authors:  Caroline Charpin; Sandrine Guis; Philippe Colson; Patrick Borentain; Jean-Pierre Mattéi; Patrice Alcaraz; Nathalie Balandraud; Benoit Thomachot; Jean Roudier; René Gérolami
Journal:  Arthritis Res Ther       Date:  2009-11-26       Impact factor: 5.156

Review 9.  Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.

Authors:  Dandan Xuan; Yiqi Yu; Linyun Shao; Jiali Wang; Wenhong Zhang; Hejian Zou
Journal:  Clin Rheumatol       Date:  2013-12-11       Impact factor: 2.980
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.